# Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ai-23-061-long-acting-drug-delivery-systems-for-art-optimization/  
Official notice: https://www.grants.gov/search-results-detail/350712

> National Institutes of Health offered grants of up to $850,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 13, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-AI-23-061 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | March 13, 2024 |
| Award ceiling | $850,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.242, 93.855, 93.865 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.

## Questions people ask

### Is RFA-AI-23-061 still open?

No. It closed on March 13, 2024.

### Who can apply for Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)?

Closed March 13, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $850,000 each.

### Who has been funded under RFA-AI-23-061?

NIH RePORTER lists 1 project funded under RFA-AI-23-061 in fiscal 2025 to 2026, at 1 institution.

### Who has won Mental Health Research Grants grants before?

The largest recipients over five fiscal years were Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, University of California, Los Angeles. The program made 6,785 awards worth $8.8 billion in that time.